[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1995

Autoimmune Disorders and Interleukin-2 Therapy: A Step Toward 'Unanswered Questions'

Author Affiliations

Department of Dermatology Hôpital Henri-Mondor 94010 Créteil Cedex, France

Créteil

Colmar, France

Villejuif, France

Paris, France

Arch Dermatol. 1995;131(5):615-616. doi:10.1001/archderm.1995.01690170119022
Abstract

We read with interest the case of ''Recurrence of Pemphigus Vulgaris Associated With Interleukin-2 Therapy'' reported by Prussick et al1 in a recent issue of the ARCHIVES. Indeed, pemphigus vulgaris (PV) and various autoimmune disorders reported during interleukin-2 immunotherapy are diseases in which interleukin-2 might play a key role. Interestingly, these diseases are rare events during interleukin-2 immunotherapy, as discussed by Gaspari in his editorial.2 In our own series of 25 patients with metastatic melanoma,3 we observed mucocutaneous lesions in 15% of 78 cycles of interleukin-2 infusion. Nine biopsy specimens were studied and did not reveal histologic or direct immunofluorescence patterns of autoimmune bullous skin diseases.

Nevertheless, we took a step toward Gaspari's ''unanswered questions'' concerning vitiligo and interleukin-2 therapy. Indeed, we had the opportunity to observe four cases of vitiligo in patients treated with interleukin-2 alone for metastatic melanoma out of our previous series of 25

First Page Preview View Large
First page PDF preview
First page PDF preview
×